<p>随着全球市场在复杂的环境中航行，亚洲股票仍然是寻求超越传统界限机会的投资者的焦点。尽管 “便士股票” 这一称谓有些过时，但由于其增长潜力和可负担性，仍然吸引着投资者的关注。本文探讨了三只展现财务实力和长期价值潜力的亚洲便士股票。</p>
<h3>亚洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.47</td>
<td>HK$909.23M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)</td>
<td>THB2.62</td>
<td>THB1.1B</td>
<td>✅ 3 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.53</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Atlantic Navigation Holdings (Singapore) (Catalist:5UL)</td>
<td>SGD0.102</td>
<td>SGD53.4M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.47</td>
<td>SGD13.66B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Anton Oilfield Services Group (SEHK:3337)</td>
<td>HK$0.77</td>
<td>HK$2.04B</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>NagaCorp (SEHK:3918)</td>
<td>HK$4.82</td>
<td>HK$21.32B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$1.00</td>
<td>NZ$137.01M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.32</td>
<td>HK$50.15B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Scott Technology (NZSE:SCT)</td>
<td>NZ$2.89</td>
<td>NZ$243.04M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲便士股票筛选器的 952 只股票的完整列表。</p>
<p>我们将查看筛选工具中一些最佳选择。</p>
<h2>上海复旦张江生物医药有限公司 (SEHK:1349)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 上海复旦张江生物医药有限公司专注于中国生物医药产品的研究、开发、生产和销售，市值为 HK$78.7 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其制药部门，最近报告的收入为 CN¥7.1163 亿。</p>
<p><strong>市值：</strong> HK$78.7B</p>
<p>上海复旦张江生物医药有限公司市值为 HK$78.7 亿，主要从制药部门产生收入，最近报告的收入为 CN¥7.1163 亿。尽管没有债务，但公司目前处于亏损状态，过去五年亏损以显著的年率增加。最近的发展包括获得中国 NMPA 对 FZ-P001 注射用钠在肺癌患者中进行二期临床试验申请的接受，可能增强其产品管线。董事会经历了变动，监督委员会解散，监督职责转移至审计委员会。</p>
<ul>
<li>点击这里发现上海复旦张江生物医药有限公司的细微差别，查看我们的详细分析财务健康报告。</li>
<li>探索历史数据，以跟踪上海复旦张江生物医药有限公司的表现，查看我们的过去业绩报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis"/></p>
<p>SEHK:1349 财务状况分析截至 2026 年 1 月</p>
<h2>博雅互动国际 (SEHK:434)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 博雅互动国际有限公司是一家投资控股公司，在中华人民共和国和香港开发和运营在线纸牌和棋盘游戏，市值为 HK$27.8 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其移动游戏相关业务，产生 HK$4.3855 亿，此外还有 HK$6.178 百万来自其 Web3 相关业务。</p>
<p><strong>市值：</strong> HK$27.8B</p>
<p>博雅互动国际市值为 HK$27.8 亿，展现出强劲的财务健康状况，因为其无债务运营，并且短期资产 HK$39 亿超过其负债。公司经历了显著的收益增长，过去一年增长了 353%，超过行业平均水平。尽管最近的指导表明，由于银行存款减少和税费增加，核心利润可能会下降，但博雅的股本回报率仍保持在 33.8% 的强劲水平。以 2.3 倍的低市盈率交易，相较于市场平均水平，表明投资者在亚洲游戏行业的便士股票中可能存在价值。</p>
<ul>
<li>点击这里了解博雅互动国际的复杂财务状况，查看我们的综合资产负债表健康报告。</li>
<li>通过查看我们的增长报告，了解博雅互动国际的收益前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis"/></p>
<p>SEHK:434 债务与股本历史及分析截至 2026 年 1 月</p>
<h2>中筑医疗控股有限公司 (SHSE:600568)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 中筑医疗控股有限公司专注于中国药物的研究、开发、生产和销售，市值为 CN¥48.7 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其在中国的运营，总计 CN¥5.7062 亿。</p>
<p><strong>市值：</strong> CN¥48.7B</p>
<p>中柱医疗控股有限公司市值为 48.7 亿人民币，运营无负债，短期资产强劲，达到 12 亿人民币，足以覆盖其负债。尽管公司未盈利，股本回报率为-32.97%，但在截至 2025 年 9 月的九个月内，净亏损已从 9242 万人民币减少至 3379 万人民币。收入从去年同期的 3.839 亿人民币增加至 4.3313 亿人民币，反映出在管理团队经验不足和董事会平均任期仅 1.1 年的挑战中，仍有一些积极的势头。</p>
<ul>
<li>在这里深入了解中柱医疗控股有限公司的具体情况，查看我们的全面资产负债表健康报告。</li>
<li>查看我们的历史业绩报告，以获取中柱医疗控股有限公司的业绩记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis"/></p>
<p>SHSE:600568 财务状况分析截至 2026 年 1 月</p>
<h2>总结</h2>
<ul>
<li>在这里发现 952 只亚洲便士股票的完整阵容。</li>
<li>想要探索一些替代方案？通过提供可靠收入来源的稳健分红股票来多样化您的投资组合，以应对潜在的市场波动。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

博雅互动

复旦张江

<p>这篇文章强调了三只亚洲便士股票，包括上海复旦张江生物医药有限公司、博雅互动国际和中珠医疗控股有限公司，这些股票显示出增长潜力。上海复旦张江专注于生物医药，市值为 78.7 亿港元，但目前尚未盈利。博雅互动的估值为 27.8 亿港元，尽管潜在利润可能下降，但其收益增长显著。中珠医疗的市值为 48.7 亿人民币，虽然也未盈利，但其净亏损同比有所减少。在复杂的市场环境中，这些股票正吸引投资者的关注</p>

<p>As global markets navigate a complex landscape, Asian stocks remain a focal point for investors seeking opportunities beyond traditional boundaries. Penny stocks, despite their somewhat outdated moniker, continue to capture interest due to their potential for growth and affordability. This article explores three Asian penny stocks that exhibit financial strength and the potential for long-term value.</p>
<div class="lb-trans"><p>随着全球市场在复杂的环境中航行，亚洲股票仍然是寻求超越传统界限机会的投资者的焦点。尽管 “便士股票” 这一称谓有些过时，但由于其增长潜力和可负担性，仍然吸引着投资者的关注。本文探讨了三只展现财务实力和长期价值潜力的亚洲便士股票。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亚洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.47</td>
<td>HK$909.23M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)</td>
<td>THB2.62</td>
<td>THB1.1B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.53</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Atlantic Navigation Holdings (Singapore) (Catalist:5UL)</td>
<td>SGD0.102</td>
<td>SGD53.4M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.47</td>
<td>SGD13.66B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Anton Oilfield Services Group (SEHK:3337)</td>
<td>HK$0.77</td>
<td>HK$2.04B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>NagaCorp (SEHK:3918)</td>
<td>HK$4.82</td>
<td>HK$21.32B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$1.00</td>
<td>NZ$137.01M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.32</td>
<td>HK$50.15B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Scott Technology (NZSE:SCT)</td>
<td>NZ$2.89</td>
<td>NZ$243.04M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.47</td>
<td>HK$909.23M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)</td>
<td>THB2.62</td>
<td>THB1.1B</td>
<td>✅ 3 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.53</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Atlantic Navigation Holdings (Singapore) (Catalist:5UL)</td>
<td>SGD0.102</td>
<td>SGD53.4M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.47</td>
<td>SGD13.66B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Anton Oilfield Services Group (SEHK:3337)</td>
<td>HK$0.77</td>
<td>HK$2.04B</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>NagaCorp (SEHK:3918)</td>
<td>HK$4.82</td>
<td>HK$21.32B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$1.00</td>
<td>NZ$137.01M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.32</td>
<td>HK$50.15B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Scott Technology (NZSE:SCT)</td>
<td>NZ$2.89</td>
<td>NZ$243.04M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 952 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲便士股票筛选器的 952 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中一些最佳选择。</p>
</div><h2>Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (SEHK:1349)</h2>
<div class="lb-trans"><h2>上海复旦张江生物医药有限公司 (SEHK:1349)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. focuses on the research, development, manufacture, and sale of bio-pharmaceutical products in China with a market cap of HK$7.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海复旦张江生物医药有限公司专注于中国生物医药产品的研究、开发、生产和销售，市值为 HK$78.7 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its pharmaceuticals segment, which generated CN¥711.63 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其制药部门，最近报告的收入为 CN¥7.1163 亿。</p>
</div><p><strong>Market Cap:</strong> HK$7.87B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$78.7B</p>
</div><p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has a market cap of HK$7.87 billion and primarily generates revenue from its pharmaceuticals segment, with CN¥711.63 million reported recently. Despite being debt-free, the company is currently unprofitable, with losses increasing over the past five years by a significant rate annually. Recent developments include receiving acceptance from China's NMPA for a Phase II clinical trial application of FZ-P001 Sodium for Injection in lung cancer patients, potentially enhancing its product pipeline. The board underwent changes with the dissolution of its Supervisory Committee, transferring oversight responsibilities to the audit committee.</p>
<div class="lb-trans"><p>上海复旦张江生物医药有限公司市值为 HK$78.7 亿，主要从制药部门产生收入，最近报告的收入为 CN¥7.1163 亿。尽管没有债务，但公司目前处于亏损状态，过去五年亏损以显著的年率增加。最近的发展包括获得中国 NMPA 对 FZ-P001 注射用钠在肺癌患者中进行二期临床试验申请的接受，可能增强其产品管线。董事会经历了变动，监督委员会解散，监督职责转移至审计委员会。</p>
</div><ul>
<li>Click here to discover the nuances of Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd with our detailed analytical financial health report.</li>
<li>Explore historical data to track Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里发现上海复旦张江生物医药有限公司的细微差别，查看我们的详细分析财务健康报告。</li>
<li>探索历史数据，以跟踪上海复旦张江生物医药有限公司的表现，查看我们的过去业绩报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis"/></p>
<p>SEHK:1349 Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:1349 财务状况分析截至 2026 年 1 月</p>
</div><h2>Boyaa Interactive International (SEHK:434)</h2>
<div class="lb-trans"><h2>博雅互动国际 (SEHK:434)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Boyaa Interactive International Limited is an investment holding company that develops and operates online card and board games in the People’s Republic of China and Hong Kong, with a market cap of HK$2.78 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 博雅互动国际有限公司是一家投资控股公司，在中华人民共和国和香港开发和运营在线纸牌和棋盘游戏，市值为 HK$27.8 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Mobile Game Related Business, generating HK$438.55 million, complemented by HK$61.78 million from its Web3 Related Business.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其移动游戏相关业务，产生 HK$4.3855 亿，此外还有 HK$6.178 百万来自其 Web3 相关业务。</p>
</div><p><strong>Market Cap:</strong> HK$2.78B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$27.8B</p>
</div><p>Boyaa Interactive International, with a market cap of HK$2.78 billion, shows strong financial health as it operates without debt and maintains high liquidity with short-term assets of HK$3.9 billion exceeding its liabilities. The company has experienced significant earnings growth, notably 353% over the past year, surpassing industry averages. Despite recent guidance indicating a potential decrease in core profit due to reduced bank deposits and increased tax expenses, Boyaa's Return on Equity remains robust at 33.8%. Trading at a low P/E ratio of 2.3x compared to the market average suggests potential value for investors seeking opportunities in penny stocks within Asia's gaming sector.</p>
<div class="lb-trans"><p>博雅互动国际市值为 HK$27.8 亿，展现出强劲的财务健康状况，因为其无债务运营，并且短期资产 HK$39 亿超过其负债。公司经历了显著的收益增长，过去一年增长了 353%，超过行业平均水平。尽管最近的指导表明，由于银行存款减少和税费增加，核心利润可能会下降，但博雅的股本回报率仍保持在 33.8% 的强劲水平。以 2.3 倍的低市盈率交易，相较于市场平均水平，表明投资者在亚洲游戏行业的便士股票中可能存在价值。</p>
</div><ul>
<li>Navigate through the intricacies of Boyaa Interactive International with our comprehensive balance sheet health report here.</li>
<li>Understand Boyaa Interactive International's earnings outlook by examining our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解博雅互动国际的复杂财务状况，查看我们的综合资产负债表健康报告。</li>
<li>通过查看我们的增长报告，了解博雅互动国际的收益前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis"/></p>
<p>SEHK:434 Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:434 债务与股本历史及分析截至 2026 年 1 月</p>
</div><h2>Zhongzhu Healthcare HoldingLtd (SHSE:600568)</h2>
<div class="lb-trans"><h2>中筑医疗控股有限公司 (SHSE:600568)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Zhongzhu Healthcare Holding Co., Ltd focuses on the research, development, production, and sale of drugs in China with a market cap of CN¥4.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中筑医疗控股有限公司专注于中国药物的研究、开发、生产和销售，市值为 CN¥48.7 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its operations in China, totaling CN¥570.62 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其在中国的运营，总计 CN¥5.7062 亿。</p>
</div><p><strong>Market Cap:</strong> CN¥4.87B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥48.7B</p>
</div><p>Zhongzhu Healthcare Holding Co., Ltd, with a market cap of CN¥4.87 billion, operates without debt and has robust short-term assets of CN¥1.2 billion, comfortably covering its liabilities. Despite being unprofitable with a negative Return on Equity of -32.97%, the company has managed to reduce its net loss from CN¥92.42 million to CN¥33.79 million year-over-year for the nine months ending September 2025. Revenue increased to CN¥433.13 million from CN¥383.9 million in the previous year, reflecting some positive momentum amidst challenges such as an inexperienced management team and board of directors with an average tenure of 1.1 years each.</p>
<div class="lb-trans"><p>中柱医疗控股有限公司市值为 48.7 亿人民币，运营无负债，短期资产强劲，达到 12 亿人民币，足以覆盖其负债。尽管公司未盈利，股本回报率为-32.97%，但在截至 2025 年 9 月的九个月内，净亏损已从 9242 万人民币减少至 3379 万人民币。收入从去年同期的 3.839 亿人民币增加至 4.3313 亿人民币，反映出在管理团队经验不足和董事会平均任期仅 1.1 年的挑战中，仍有一些积极的势头。</p>
</div><ul>
<li>Dive into the specifics of Zhongzhu Healthcare HoldingLtd here with our thorough balance sheet health report.</li>
<li>Review our historical performance report to gain insights into Zhongzhu Healthcare HoldingLtd's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解中柱医疗控股有限公司的具体情况，查看我们的全面资产负债表健康报告。</li>
<li>查看我们的历史业绩报告，以获取中柱医疗控股有限公司的业绩记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis"/></p>
<p>SHSE:600568 Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:600568 财务状况分析截至 2026 年 1 月</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Discover the full array of 952 Asian Penny Stocks right here.</li>
<li>Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里发现 952 只亚洲便士股票的完整阵容。</li>
<li>想要探索一些替代方案？通过提供可靠收入来源的稳健分红股票来多样化您的投资组合，以应对潜在的市场波动。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

上海复旦张江生物医药有限公司及其他两只亚洲低价股值得密切关注